Dessislava Lazarova

Prof. Dr. Dessislava Lazarova

Faculty of Medicine, Sofia University St. Kliment Ohridski, Sofia, Sofia-Grad, Bulgaria

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2013 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
ZZZhivko Zhelev
Zhivko Zhelev
RBRumiana Bakalova
Rumiana Bakalova
IAIchio Aoki
Ichio Aoki
DLDessislava Lazarova
Dessislava Lazarova
TSTsuneo Saga
Tsuneo Saga

17 January 2014
Verified
Journal Article
Closed access
DIDonika Ivanova
Donika Ivanova
RBRumiana Bakalova
Rumiana Bakalova
DLDessislava Lazarova
Dessislava Lazarova
VGVeselina Gadjeva
Veselina Gadjeva
ZZZhivko Zhelev
Zhivko Zhelev

19 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ASAkira Sumiyoshi
Akira Sumiyoshi
SSSayaka Shibata
Sayaka Shibata
ZZZhivko Zhelev
Zhivko Zhelev
TMThomas Miller
Thomas Miller
DLDessislava Lazarova
Dessislava Lazarova
RBRumiana Bakalova
Rumiana Bakalova
Glioblastoma is one of the most aggressive brain tumors, characterized by a pronounced redox imbalance, expressed in a high oxidative capacity of cancer cells due to their elevated glycolytic and mitochondrial oxidative metabolism. The assessment and modulation of the redox state of glioblastoma are crucial factors that can provide highly specific targeting and treatment. Our study describes a pharmacological strategy for targeting glioblastoma using a redox-active combination drug. The experiments were conducted in vivo on glioblastoma mice (intracranial model) and in vitro on cell lines (cancer and normal) treated with the redox cycling pair menadione/ascorbate (M/A). The following parameters were analyzed in vivo using MRI or ex vivo on tissue and blood specimens: tumor growth, survival, cerebral perfusion, cellular density, tissue redox state, expression of tumor-associated NADH oxidase (tNOX) and transforming growth factor-beta 1 (TGF-β1). Dose-dependent effects of M/A on cell viability, mitochondrial functionality, and redox homeostasis were evaluated in vitro. M/A treatment suppressed tumor growth and significantly increased survival without adverse side effects. This was accompanied by increased oxidative stress, decreased reducing capacity, and decreased cellular density in the tumor only, as well as increased cerebral perfusion and down-regulation of tNOX and TGF-β1. M/A induced selective cytotoxicity and overproduction of mitochondrial superoxide in isolated glioblastoma cells, but not in normal microglial cells. This was accompanied by a significant decrease in the over-reduced state of cancer cells and impairment of their “pro-oncogenic” functionality, assessed by dose-dependent decreases in: NADH, NAD+, succinate, glutathione, cellular reducing capacity, mitochondrial potential, steady-state ATP, and tNOX expression. The safety of M/A on normal cells was compromised by treatment with cerivastatin, a non-specific prenyltransferase inhibitor. In conclusion, M/A differentiates glioblastoma cells and tissues from normal cells and tissues by redox targeting, causing severe oxidative stress only in the tumor. The mechanism is complex and most likely involves prenylation of menadione in normal cells, but not in cancer cells, modulation of the immune response, a decrease in drug resistance, and a potential role in sensitizing glioblastoma to conventional chemotherapy.

26 November 2014 in Biotechnology & Biotechnological Equipment
Verified
Journal Article
Open access
RBRumiana Bakalova
Rumiana Bakalova
DLDessislava Lazarova
Dessislava Lazarova
BNBiliana Nikolova
Biliana Nikolova
SASeverina Atanasova
Severina Atanasova
GZGenoveva Zlateva
Genoveva Zlateva
IAIchio Aoki
Ichio Aoki
The present study was designed to investigate whether poly-ion complex hollow vesicles (polymersomes), based on chemically modified chitosan, are appropriate for passive tumour targeting in the context of their application as drug carriers. The experiments were performed on colon cancer-grafted mice. The mice were subjected to anaesthesia and injected intravenously with water-soluble nanoparticles: (1) QD(705)-labelled polymersomes (average size approximate to 120nm; size distribution approximate to 10%) or (2) native QD(705). The optical imaging was carried out on Maestro EX 2.10 In Vivo Imaging System (excitation filter 435-480nm; emission filter 700nm, longpass). In the case of QD(705), the fluorescence appeared in the tumour area within 1min after injection and disappeared completely within 60min. A strong fluorescent signal was detected in the liver on the 30th minute. The visualization of tumour using QD(705) was based only on angiogenesis. In the case of QD(705)-labelled polymersomes, the fluorescence appeared in the tumour area immediately after injection with excellent visualization of blood vessels in the whole body. A strong fluorescent signal was detected in the tumour area within 16hours. This indicated that QD(705)-labelled polymersomes were delivered predominantly into the tumour due to their long circulation in the bloodstream and enhanced permeability and retention effect. A very weak fluorescent signal was found in the liver area. The data suggest that size-controlled long-circulating polymersomes are very promising carriers for drug delivery in solid tumours, including delivery of small nanoparticles and contrast substances.

10 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ZZZhivko Zhelev
Zhivko Zhelev
ASAkira Sumiyoshi
Akira Sumiyoshi
IAIchio Aoki
Ichio Aoki
DLDessislava Lazarova
Dessislava Lazarova
Tatyana VlaykovaTatyana Vlaykova
Tatyana Vlaykova
RBRumiana Bakalova
Rumiana Bakalova
A considerable amount of data have accumulated in the last decade on the pronounced mitochondrial fatty acid oxidation (mFAO) in many types of cancer cells. As a result, mFAO was found to coexist with abnormally activated fatty acid synthesis (FAS) and the mevalonate pathway. Recent studies have demonstrated that overactivated mitochondrial β-oxidation may aggravate the impaired mitochondrial redox state and vice versa. Furthermore, the impaired redox state of cancerous mitochondria can ensure the continuous operation of β-oxidation by disconnecting it from the Krebs cycle and connecting it to the citrate–malate shuttle. This could create a new metabolic state/pathway in cancer cells, which we have called the “β-oxidation-citrate–malate shuttle”, or “β-oxidation shuttle” for short, which forces them to proliferate. The calculation of the phosphate/oxygen ratio indicates that it is inefficient as an energy source and must consume significantly more oxygen per mole of ATP produced when combined with acetyl-CoA consuming pathways, such as the FAS and mevalonate pathways. The “β-oxidation shuttle” is an unconventional mFAO, a separate metabolic pathway that has not yet been explored as a source of energy, as well as a source of cataplerosis, leading to biomass accumulation, accelerated oxygen consumption, and, ultimately, a source of proliferation. The role of the “β-oxidation shuttle” and its contribution to redox-altered cancer metabolism provides a new direction for the development of future anticancer strategies. This may represent the metabolic “secret” of cancer underlying hypoxia and genomic instability.

1 January 2009 in Physiology and Molecular Biology of Plants
Verified
Journal Article
Closed access
PDF file
MVMaya Velitchkova
Maya Velitchkova
DLDessislava Lazarova
Dessislava Lazarova
APAntoaneta V. Popova
Antoaneta V. Popova